Newcells Biotech
2014
FOUNDED
PRIVATE
STATUS
Early Stage VC
LATEST DEAL TYPE
$7M
LATEST DEAL AMOUNT
2
INVESTORS
Description
Developer of a technology designed to produce induced pluripotent stem cells. The company's platform is at the forefront of the production and differentiation of human induced pluripotent stem cells (hiPSC), which is quickly advancing the field of pre-clinical disease modeling and drug safety evaluation, enabling researchers to research and test new drugs and screen potential drug molecules for efficacy and toxicity.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
- Biomedicine West International Centre for Life
- Times Square
- Newcastle upon Tyne NE1 4EP
- England, United Kingdom
+44 0191 000 0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Newcells Biotech’s full profile, request a free trial.
Newcells Biotech Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC | $7M | 00.00 | Completed | Generating Revenue | ||
| 3. Early Stage VC | 04-Jul-2018 | 00.000 | 00.000 | 00.000 | Completed | Generating Revenue |
| 2. Grant | 10-Oct-2016 | $239K | Completed | Generating Revenue | ||
| 1. Seed Round | 02-Sep-2015 | $239K | $239K | 00.000 | Completed | Generating Revenue |
Newcells Biotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| D2 Ordinary | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| D1 Ordinary | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| C Ordinary | 337,969 | $0.000133 | $1.96 | $1.96 | 1x | $1.96 | 11.67% | |
| Ordinary A | 29,500 | $0.000133 | $6.9 | $6.9 | 1x | $6.9 | 1.02% |
Newcells Biotech Competitors (26)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DefiniGEN | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 00.000 | 0000000000 0 | 00.000 |
| 000 0000000000000 | Venture Capital-Backed | Seattle, WA | 00 | 000.00 | 0000000000 0 | 000.00 |
| 0000000 | Venture Capital-Backed | Gosselies, Belgium | 00 | 000.00 | 0000000000 0 | 000.00 |
| 0000 00000000000 | Private Equity-Backed | Cambridgeshire, United Kingdom | 00 | 00.000 | 0000000 0000 | 00.000 |
| 0000000 | Formerly VC-backed | Leuven, Belgium | 00 | 00000 | 000000&0 | 00000 |
Newcells Biotech Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| NVM Private Equity | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| Northstar Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
Newcells Biotech Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Michael Nicholds | Chief Executive Officer & Board Member | ||
| Lyle Armstrong Ph.D | Board Member & Chief Scientific Officer | ||
| Majlinda Lako Ph.D | Scientific Founder |
Newcells Biotech Board Members (4)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Lyle Armstrong Ph.D | Newcells Biotech | Board Member & Chief Scientific Officer | 000 0000 | |
| Michael Nicholds | Newcells Biotech | Chief Executive Officer & Board Member | 000 0000 | |
| Sandy Primrose | Self | Non-Executive Chairman | 000 0000 | |
| Timothy Levett | NVM Private Equity | Board Member | 000 0000 |